The Latest Progress Of Targeted Therapy Non-samll Cell Lung Cancer With Brain Metastases

To enter the 21 st century,the incidence rate of the cancer is increasing year by year.The lung cancer is not only the most common tumor,but also the tumor of death rate in all malignant tumor.There will be over 1.8 million newly increasing patients of lung carcinoma a year in the worldaround.Non small cell lung cancer accounted for 80%-85%,at the same time about 10%-25% of patients has been associated with brain metastases.They have poor quality of life,the median overall survival was only 3-6 months with brain metastasis.There are various treatment methods: surgical treatment,whole brain radiotherapy(WBRT),stereotactic radiotherapy(SRS),chemotherapy.These methods can improve the patient's ove rall survival,but too much secondary reaction.In the 2004,the FDA approved the first generation EGFR-TKIs drugs,Erlotinb after the listing.These targeted drugs have reports in patients non small cell lung cancer with brain metastasis.Therefore,the molecular targeted therapy is an important means of non-small cell lung cancer with brain metastasis.In recent years,with the development of oncology and the progress of gene sequencing.The molecular targeting therapy of lung cancer has been developed rapidly.Non small cell lung cancer with brain metastasis can really achievely accurate treatment.This paper focuses on the molecular target in patients with non-small cell lung cancer with brain metastasis.